Week in Review: Tsinghua University Invests $276 Million in Cambridge UK Biohub

Deals and Financings 

• Beijing's Tsinghua University will invest $276 million in a JV to build a new biohub in the UK's Cambridge Science Park;
• Jing Medicine (Shanghai) formed a $100 million collaboration to develop small molecule cancer drugs with ShanghaiTech University;
• Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital to develop novel drugs for cancer and autoimmune diseases;
• China's GeneScience was a new investor in Rani Therapeutics' latest $53 million funding for its oral drug delivery of injectible drugs;  
• Cellular Biomedicine, a China-US biopharma, raised $30.6 million from Sailing Capital to support a CAR-T immunotherapy;
• Luqa Pharma of Hong Kong closed a $15 million Series B financing round to develop a portfolio of in-licensed dermatology and aesthetic products for China;  
• Roivant Sciences, a Swiss-US in-licensing company, will collaborate with ArQule to develop a cancer treatment in China;
• NetVation DL Medicine, a Chengdu subsidiary of HitGen, entered a two-year research collaboration to discover new drugs for Pfizer;
• Zhejiang Haichang Biotech will develop a new formulation of a Rexahn liver cancer treatment for China use;  
• China Resources Pharma acquired China rights to a long-acting treatment for prostate cancer from Sweden's Xbrane Biopharma;

Trials and Approvals 

• Hong Kong's Golden Meditech was granted FDA GMP certification for its Houston T-Cell processing facility;
• Beijing's BeiGene launched a Celgene cancer drug, Vidaza®, in China.

Stock Symbols: (NSDQ: CBMG) (NSDQ: ARQL) (NYSE: PFE) (NYSE American: RNN) (HK: 3320) (HK: 00801) (NSDQ: BGNE) (NSDQ: CELG)

Share this with colleagues:

Original Article: Week in Review: Tsinghua University Invests $276 Million in Cambridge UK Biohub

More From BioPortfolio on "Week in Review: Tsinghua University Invests $276 Million in Cambridge UK Biohub"